Palisade Bio Inc (PALI)

$1.89 -0.10 (-5.03%)
Market Cap 293.54M
Revenue (ttm) 0.00
Net Income (ttm) -14.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 2,956,100
Avg Vol 4,056,148
Day's Range N/A - N/A
Shares Out 149.00M
Stochastic %K 43%
Beta 1.53
Analysts Strong Sell
Price Target $12.00

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement wi...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4900
Address:
7750 El Camino Real, Suite 2A, Carlsbad, United States
masonat
masonat Mar. 20 at 4:08 PM
$PALI So...probably next week
0 · Reply
RNJen
RNJen Mar. 19 at 6:37 PM
$PALI - This wall at $2.00 keeps getting bigger and bigger. We need some buying volume!
0 · Reply
StMichaelTwits
StMichaelTwits Mar. 19 at 6:32 PM
$PALI Time to load Shhhhhh 🤫👇😘 Drug: PALI-2108 Announced Date: October 20, 2025 Target Action Date: Q1 2026 Estimated Target Date Range: January 1, 2026 - 👉👉 latest March 31, 2026👈👈 Indication: For patients affected by UC.
0 · Reply
KoreanSpiderman
KoreanSpiderman Mar. 19 at 2:13 AM
$PALI Even Moderate FSCD results justifies 8$ TP. UC results are oustanding. expecting topline readouts next week.
0 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 16 at 3:47 PM
$DTIL My Bio additions this yr $RCKT $RNAC $PALI $SMMT
0 · Reply
Stocktwits019475
Stocktwits019475 Mar. 16 at 2:51 PM
$PALI Isn’t it nice when a stock has a solid floor? Now we just wait for news 😎
0 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 16 at 1:49 PM
$PALI 50k share 💪. Let’s go $10 plus 🚀
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 14 at 6:44 PM
I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.
0 · Reply
Sowa5000
Sowa5000 Mar. 13 at 2:43 PM
$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!
1 · Reply
BOUDIN420
BOUDIN420 Mar. 12 at 10:08 PM
$PALI is 91% institutionally owned with P1b Topline Data due in Q1 for Crohn's disease. This Dual asset could be Beast for ulcerative colitis and Crohn's disease considering it's last P1b data release for ulcerative colitis. I believe that's why there are so many institutions involved here.
1 · Reply
Latest News on PALI
Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Mar 2, 2026, 9:00 AM EST - 19 days ago

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Feb 23, 2026, 8:40 AM EST - 26 days ago

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Feb 17, 2026, 8:45 AM EST - 4 weeks ago

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 9, 2026, 9:00 AM EST - 5 weeks ago

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 5, 2026, 8:45 AM EST - 6 weeks ago

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Jan 29, 2026, 8:45 AM EST - 7 weeks ago

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Jan 16, 2026, 8:30 AM EST - 2 months ago

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Jan 7, 2026, 8:15 AM EST - 2 months ago

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Dec 30, 2025, 8:35 AM EST - 2 months ago

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Palisade Bio: Gut Prodrug For IBD With Catalysts

Dec 22, 2025, 8:45 PM EST - 3 months ago

Palisade Bio: Gut Prodrug For IBD With Catalysts

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Dec 2, 2025, 8:45 AM EST - 3 months ago

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:45 AM EST - 4 months ago

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:45 AM EDT - 5 months ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 20, 2025, 8:45 AM EDT - 5 months ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 13, 2025, 8:45 AM EDT - 5 months ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 9, 2025, 5:00 PM EDT - 5 months ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 2, 2025, 4:05 PM EDT - 6 months ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Oct 1, 2025, 9:20 AM EDT - 6 months ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 26, 2025, 4:05 PM EDT - 6 months ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 17, 2025, 9:00 AM EDT - 6 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:45 AM EDT - 7 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 25, 2025, 9:00 AM EDT - 7 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 7, 2025, 9:15 AM EDT - 8 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 31, 2025, 8:45 AM EDT - 8 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 23, 2025, 8:00 PM EDT - 8 months ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 8 months ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Jul 9, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:30 AM EDT - 10 months ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025, 8:30 AM EDT - 11 months ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025, 8:30 AM EDT - 11 months ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Apr 9, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Mar 4, 2025, 8:30 AM EST - 1 year ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 20, 2025, 8:45 AM EST - 1 year ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Feb 10, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 29, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 5:20 PM EST - 1 year ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 17, 2024, 8:30 AM EST - 1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

What's Going On With Palisade Bio Stock On Thursday?

Dec 12, 2024, 12:55 PM EST - 1 year ago

What's Going On With Palisade Bio Stock On Thursday?

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:05 PM EST - 1 year ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Dec 3, 2024, 8:15 AM EST - 1 year ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Nov 21, 2024, 8:15 AM EST - 1 year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Nov 12, 2024, 8:45 AM EST - 1 year ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

masonat
masonat Mar. 20 at 4:08 PM
$PALI So...probably next week
0 · Reply
RNJen
RNJen Mar. 19 at 6:37 PM
$PALI - This wall at $2.00 keeps getting bigger and bigger. We need some buying volume!
0 · Reply
StMichaelTwits
StMichaelTwits Mar. 19 at 6:32 PM
$PALI Time to load Shhhhhh 🤫👇😘 Drug: PALI-2108 Announced Date: October 20, 2025 Target Action Date: Q1 2026 Estimated Target Date Range: January 1, 2026 - 👉👉 latest March 31, 2026👈👈 Indication: For patients affected by UC.
0 · Reply
KoreanSpiderman
KoreanSpiderman Mar. 19 at 2:13 AM
$PALI Even Moderate FSCD results justifies 8$ TP. UC results are oustanding. expecting topline readouts next week.
0 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 16 at 3:47 PM
$DTIL My Bio additions this yr $RCKT $RNAC $PALI $SMMT
0 · Reply
Stocktwits019475
Stocktwits019475 Mar. 16 at 2:51 PM
$PALI Isn’t it nice when a stock has a solid floor? Now we just wait for news 😎
0 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 16 at 1:49 PM
$PALI 50k share 💪. Let’s go $10 plus 🚀
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 14 at 6:44 PM
I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.
0 · Reply
Sowa5000
Sowa5000 Mar. 13 at 2:43 PM
$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!
1 · Reply
BOUDIN420
BOUDIN420 Mar. 12 at 10:08 PM
$PALI is 91% institutionally owned with P1b Topline Data due in Q1 for Crohn's disease. This Dual asset could be Beast for ulcerative colitis and Crohn's disease considering it's last P1b data release for ulcerative colitis. I believe that's why there are so many institutions involved here.
1 · Reply
Dusty_Bunz
Dusty_Bunz Mar. 12 at 5:37 PM
$PALI 2.04 - 2.13
0 · Reply
BOUDIN420
BOUDIN420 Mar. 12 at 4:01 PM
$PALI
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 11 at 8:43 PM
$PALI left something on 1.97 sub 1 stock 4 later coming up ! 3 of them!
0 · Reply
100K2022
100K2022 Mar. 11 at 12:54 PM
$PALI I would love to see this break 2.00 today
0 · Reply
specctham
specctham Mar. 7 at 9:58 AM
$PALI 5
0 · Reply
masonat
masonat Mar. 5 at 3:18 AM
$PALI Chron's data this month. Probably won't be a huge catalyst but we'll see.
1 · Reply
Quasi3
Quasi3 Mar. 4 at 8:08 PM
$PALI guys it looks like we would be on a wave B and then C… up to 1.2 ?
0 · Reply
Quasi3
Quasi3 Mar. 4 at 2:55 PM
$PALI will we touch 1.2$?
0 · Reply
MajorBigBull
MajorBigBull Mar. 3 at 3:59 PM
$PALI
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 12:44 AM
$PALI RSI: 57.14, MACD: -0.0001 Vol: 0.10, MA20: 1.70, MA50: 1.85 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 1 at 12:37 AM
I’m especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I’ll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.
0 · Reply
100K2022
100K2022 Feb. 27 at 7:02 PM
$PALI anyone buying more here?
0 · Reply